申请人:SCINOPHARM TAIWAN, LTD.
公开号:US20180057464A1
公开(公告)日:2018-03-01
Provided herein are novel processes and methods for making 4-[(3-[(4-cyclopropylcarbonyl)piperazin-1-yl]carbonyl)-4-fluorophenyl]methyl(2H)phthalazin-1-one (Olaparib) and intermediates thereof. Olaparib is a poly ADP ribose polymerase (PARP) inhibitor useful in the treatment of cancers. Benefits of the present disclosure include the use of less toxic compounds and improved yields.
本文提供了制备4-[(3-[(4-环丙烷甲酰)piperazin-1-yl]甲酰)-4-氟苯基]甲基(2H)邻苯二酮(奥拉帕尼)及其中间体的新型工艺和方法。奥拉帕尼是一种聚ADP核糖聚合酶(PARP)抑制剂,可用于治疗癌症。本公开的益处包括使用毒性更小的化合物和提高产量。